Cipla gets USFDA EIR for Bommasandra API facility
Advertisement
Bangalore: Cipla has announced that it has received Establishment Inspection Report (EIR) from USFDA for its API manufacturing facility in Bommasandra, Bangalore, indicating closure of the inspection.
USFDA had inspected the facility from January 20, 2020, to January 24, 2020.
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India.
The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.